The most striking finding from our CRISPR screens was the potent enrichment of gRNAs targeting GNA13, as well as its upstream receptors S1PR2 and P2RY8. Inactivating mutations of GNA13 are common in lymphoma, but rarely seen in other forms of malignancy. This evidence concerns the gene P2RY8 and lymphoma.